Zhengye Biotechnology Holding Limited

Healthcare · Drug Manufacturers - Specialty & Generic

1.20$ -4.0% vs. previous close Closing price · As of: Oct 5, 2026

Statements

Income Statement

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

Tick rows to compare them in a chart (up to 4)

Income Statement ZYBT
Line item	Q3 25	Q1 26
Revenue	0.57	1.12
Cost of Revenue	0.52	1.03
Gross Profit	0.05	0.09
Research & Development	0.10	0.19
Selling, General & Administrative	0.17	–
Total Operating Expenses	0.49	0.96
Operating Income	-0.44	-0.86
Interest Expense	0.02	0.03
Pre-Tax Income	-0.43	-0.85
Income Tax Expense	0.17	0.34
Net Income	-0.51	-1.00
EBITDA	-0.30	-0.58

Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?